ONCT Oncternal Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ONCT

Price (delayed)

$8.745

Market cap

$25.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.43

Enterprise value

$19.5M

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on ...

Highlights
The EPS is up by 20% year-on-year and by 7% since the previous quarter
Oncternal Therapeutics's net income has increased by 11% YoY and by 5% QoQ
ONCT's revenue is down by 47% year-on-year but it is up by 19% since the previous quarter
The gross profit has contracted by 47% YoY but it has grown by 19% from the previous quarter
ONCT's equity has plunged by 51% YoY and by 19% from the previous quarter
The quick ratio has contracted by 21% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oncternal.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ONCT
Market
Shares outstanding
2.96M
Market cap
$25.88M
Enterprise value
$19.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
32.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.84
Earnings
Revenue
$785,000
EBIT
-$39.48M
EBITDA
-$39.31M
Free cash flow
-$32.16M
Per share
EPS
-$13.43
Free cash flow per share
-$10.94
Book value per share
$10.19
Revenue per share
$0.27
TBVPS
$12.49
Balance sheet
Total assets
$36.73M
Total liabilities
$6.68M
Debt
$318,000
Equity
$30.05M
Working capital
$30.86M
Liquidity
Debt to equity
0.01
Current ratio
6.94
Quick ratio
6.59
Net debt/EBITDA
0.16
Margins
EBITDA margin
-5,007%
Gross margin
100%
Net margin
-5,029.2%
Operating margin
-5,313.9%
Efficiency
Return on assets
-83.6%
Return on equity
-95.9%
Return on invested capital
-130.8%
Return on capital employed
-125.2%
Return on sales
-5,029.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ONCT stock price

How has the Oncternal Therapeutics stock price performed over time
Intraday
9.31%
1 week
6%
1 month
-5.66%
1 year
28.15%
YTD
-18.45%
QTD
-2.83%

Financial performance

How have Oncternal Therapeutics's revenue and profit performed over time
Revenue
$785,000
Gross profit
$785,000
Operating income
-$41.71M
Net income
-$39.48M
Gross margin
100%
Net margin
-5,029.2%
The operating margin has dropped by 76% year-on-year but it has increased by 20% since the previous quarter
Oncternal Therapeutics's net margin has plunged by 70% YoY but it has increased by 21% from the previous quarter
ONCT's revenue is down by 47% year-on-year but it is up by 19% since the previous quarter
The gross profit has contracted by 47% YoY but it has grown by 19% from the previous quarter

Growth

What is Oncternal Therapeutics's growth rate over time

Valuation

What is Oncternal Therapeutics stock price valuation
P/E
N/A
P/B
0.86
P/S
32.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.84
The EPS is up by 20% year-on-year and by 7% since the previous quarter
ONCT's price to book (P/B) is 57% less than its 5-year quarterly average of 2.0 but 23% more than its last 4 quarters average of 0.7
ONCT's equity has plunged by 51% YoY and by 19% from the previous quarter
ONCT's revenue is down by 47% year-on-year but it is up by 19% since the previous quarter
ONCT's price to sales (P/S) is 6% lower than its last 4 quarters average of 34.8

Efficiency

How efficient is Oncternal Therapeutics business performance
The return on invested capital has surged by 89% year-on-year and by 6% since the previous quarter
The return on sales has dropped by 70% year-on-year but it is up by 21% since the previous quarter
ONCT's return on equity has dropped by 54% year-on-year and by 12% since the previous quarter
The return on assets has declined by 47% year-on-year and by 11% since the previous quarter

Dividends

What is ONCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONCT.

Financial health

How did Oncternal Therapeutics financials performed over time
The company's total assets fell by 46% YoY and by 15% QoQ
The current ratio has contracted by 21% YoY and by 16% from the previous quarter
Oncternal Therapeutics's debt is 99% less than its equity
ONCT's equity has plunged by 51% YoY and by 19% from the previous quarter
Oncternal Therapeutics's debt has decreased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.